Indivior PLC (NASDAQ:INDV) Receives $45.17 Consensus Price Target from Brokerages

Indivior PLC (NASDAQ:INDV) has received an average recommendation of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $45.1667.

Several equities research analysts recently weighed in on the stock. Zacks Research downgraded shares of Indivior from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 29th. Barclays lowered their price objective on Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 5th. Craig Hallum reiterated a “buy” rating and set a $53.00 target price on shares of Indivior in a research note on Tuesday, August 4th. Finally, Weiss Ratings raised Indivior from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, September 4th.

Indivior Price Performance

Shares of Indivior stock opened at $36.19 on Friday. The stock has a market cap of $4.27 billion, a price-to-earnings ratio of 12.97 and a beta of 0.82. The firm’s 50-day moving average is $37.41 and its 200 day moving average is $36.18. Indivior has a 1 year low of $22.56 and a 1 year high of $42.81.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Tuesday, June 30th. The company reported $5.75 earnings per share for the quarter. The business had revenue of $343.00 million during the quarter. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%. On average, equities analysts expect that Indivior will post 3.66 EPS for the current fiscal year.

Indivior Announces Dividend

The firm also recently disclosed a special dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 30th will be issued a $8.13 dividend. The ex-dividend date is Friday, October 30th.

Insider Transactions at Indivior

In related news, CAO Woodrow D. Anderson purchased 1,500 shares of the company’s stock in a transaction dated Thursday, August 27th. The shares were purchased at an average price of $35.69 per share, with a total value of $53,535.00. Following the acquisition, the chief accounting officer directly owned 27,638 shares in the company, valued at $986,400.22. The trade was a 5.74% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Christian Heidbreder sold 18,586 shares of Indivior stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $41.14, for a total transaction of $764,628.04. Following the completion of the sale, the insider owned 209,337 shares of the company’s stock, valued at $8,612,124.18. This represents a 8.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.74% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Indivior

Hedge funds have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Indivior by 72.7% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after buying an additional 460 shares during the last quarter. Rockefeller Capital Management L.P. increased its holdings in Indivior by 512.4% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock valued at $46,000 after buying an additional 1,076 shares during the last quarter. TD Waterhouse Canada Inc. purchased a new stake in Indivior during the second quarter valued at approximately $63,000. GAMMA Investing LLC bought a new position in Indivior in the second quarter worth approximately $66,000. Finally, ProShare Advisors LLC raised its position in Indivior by 15.7% in the fourth quarter. ProShare Advisors LLC now owns 29,139 shares of the company’s stock worth $1,046,000 after acquiring an additional 3,949 shares during the period. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company focused on developing and commercializing medicines for addiction and serious mental health disorders. Its portfolio is primarily centered on treatments for opioid use disorder, with an emphasis on products designed to support recovery, reduce illicit opioid use and address the risk of overdose.

The company’s key products include SUBOXONE sublingual film, a buprenorphine-and-naloxone treatment for opioid use disorder; SUBLOCADE, a long-acting injectable form of buprenorphine; and OPVEE, a nalmefene nasal spray intended for the emergency treatment of opioid overdose.